Loading organizations...
neuroClues is a technology company.
NeuroClues develops an eye-tracking environment designed to quantify clinical neurological exams instantly. Its technology leverages extensive scientific research linking eye movements to various neurological conditions, translating this knowledge into practical diagnostic tools. The core product provides biomarkers, enabling practitioners to assess neurological health efficiently.
Founded by Antoine Pouppez, CEO, and Pierre Daye, CTO, NeuroClues emerged from a collective insight among researchers, doctors, and engineers. They recognized the potential to apply established eye-tracking science to clinical settings, driven by a mission to enhance neurological care. Their combined expertise underpins the company's approach to advanced diagnostic capabilities.
NeuroClues targets clinicians, empowering them with early diagnostic biomarkers for conditions like Parkinson's Disease, Alzheimer's Disease, and Multiple Sclerosis, often before visible symptoms appear. The company's vision is to support 10 million patients by 2030, striving to be a pragmatic healthcare company that enables proactive neurological intervention and improved patient outcomes.
neuroClues has raised $15.2M across 3 funding rounds.
neuroClues has raised $15.2M in total across 3 funding rounds.
neuroClues is a French-Belgian MedTech startup developing a portable, CE-marked Class IIa medical device based on eye-tracking technology to empower clinicians with biomarkers for early detection of neurological disorders like Parkinson’s Disease, Alzheimer’s Disease, and Multiple Sclerosis—years before visible symptoms appear.[1][2][3] The device, often called a "brain stethoscope," provides non-invasive, quick analysis of eye movements in an easy-to-use clinical environment, targeting neurologists and aiming to support 10 million patients by 2030 amid rising prevalence (e.g., Parkinson’s cases doubling to 13 million).[1][3][5] It serves healthcare practitioners in Europe (currently available post-CE marking) and is pursuing US regulatory approvals, with strong growth via €4.7M seed (2021), €2.5M EIC grant plus up to €9M equity (2022), and €5M pre-Series A (2024) to enable commercial rollout.[1][2]
Founded in 2020 as P3Lab (rebranded to neuroClues), the company emerged from over 35 years of combined research by a team of researchers, doctors, and engineers focused on eye movement studies through modeling and experimental projects.[1][2] Frustrated by limitations in existing eye-tracking tools for clinical use, founders—including key figures who pursued eye movement research—teamed up with Antoine Pouppez to create NeuroClues™, a medical device unlocking eye-tracking's potential for early neurological diagnosis.[1] Pivotal early traction included incubation at iPEPS-ICM (Paris-Salpêtrière hospital incubator and STATION F healthtech partner), partnership with Paris Brain Institute, and international collaborations; funding momentum accelerated with the €4.7M seed in November 2021, followed by EIC support and 2024 pre-Series A.[1][2]
neuroClues rides the wave of AI-driven digital health and precision neurology, leveraging eye-tracking—a mature field with decades of evidence—to enable pre-symptomatic detection amid surging neurological disorder prevalence (1 in 3 affected globally).[1][3] Timing aligns with aging populations and post-pandemic medtech acceleration, where non-invasive biomarkers fill gaps in subjective diagnostics; market forces like EIC funding and US expansion favor scalable deep tech like this.[1][2] It influences the ecosystem by democratizing advanced research (e.g., via portable tools) for routine care, fostering collaborations across Europe/US hospitals and incubators like STATION F, and paving the way for broader adoption of eye-based biomarkers in neurology.[2][5]
With €5M pre-Series A fueling US regulatory approvals and commercial deployment, neuroClues is poised for 2025-2030 scale toward its 10M-patient goal, potentially debuting at CES 2025 to boost visibility.[1][5] Trends like AI-biomarker integration and global medtech harmonization (e.g., FDA pathways) will propel growth, evolving its role from European pioneer to global standard-setter in early neurologic care—transforming "biomarkers in a blink" from research passion to clinical reality.[1][3]
neuroClues has raised $15.2M in total across 3 funding rounds.
neuroClues's investors include European Commission, Eric Brandt, Fiona du Monceau, Olivier Legrain, Invest.BW, Francois-Xavier de Mevius, Jean Charles Samuelian, Mathieu de Lophem, Artwall, Sebastien de Halleux, Pierre de Waha, Thibault Jonckheere.
neuroClues has raised $15.2M across 3 funding rounds. Most recently, it raised $5.4M Pre-Series A in April 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 30, 2024 | $5.4M Pre-Series A | European Commission, Eric Brandt | Fiona du Monceau, Olivier Legrain, Invest.BW |
| Nov 8, 2021 | $4.9M Other Equity | Fiona du Monceau, Francois-Xavier de Mevius, Jean Charles Samuelian, Mathieu de Lophem, Artwall, Sebastien de Halleux, Pierre de Waha | Olivier Legrain, Thibault Jonckheere, DGO6, Novalia |
| Nov 1, 2021 | $5.0M Seed | 8VC, ARCH Venture Partners, Graph Ventures, Kima Ventures, Lux Capital, Scott Gottlieb, Picus Capital, #SecretFund, Ivan Markman, Roxanne Varza |